UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta® in the prophylactic treatment of chemotherapy-induced neutropenia

European journal of cancer (1990), 2017-02, Vol.72, p.S42-S42

2017

Volltextzugriff (PDF)

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Annals of oncology, 2021-10, Vol.32 (10), p.1245-1255

2021

Volltextzugriff (PDF)

256 - Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta® in the prophylactic treatment of chemotherapy-induced neutropenia

European journal of cancer (1990), 2017-02, Vol.72, p.S42-S42

2017

Volltextzugriff (PDF)

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia

Annals of oncology, 2016-10, Vol.27, p.vi497-vi497

2016

Volltextzugriff (PDF)

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

ESMO open, 2022-04, Vol.7 (2), p.100408-100408, Article 100408

2022

Volltextzugriff (PDF)

The immunological profile of patients with chronic recurrent pancreatitis

Sovetskaia meditsina, 1985 (4), p.24

1985

Volltextzugriff (PDF)

Use of basophil degranulation for detecting sensitivity to antigens in rheumatism

Laboratornoe delo, 1979 (6), p.330

1979

Volltextzugriff (PDF)

Model for detection of the state of delayed hypersensitivity in patients with rheumatism with minimal degree of the activity of the process

Laboratornoe delo, 1977-06 (6), p.341

1977

Volltextzugriff (PDF)

Treatment of acute uncomplicated cystitis in women with antibiotic allergy or intolerance

Urologii͡a︡ (Moscow, Russia : 1999), 2019-12, Vol.5_2019 (5), p.64-71

2019

Volltextzugriff (PDF)

Effect of dietotherapy on the blood serum protein content of patients with torpid and latent recurrent rheumocarditis

Voprosy pitaniia, 1986-03 (2), p.11

Voĭtko, N E

1986

Volltextzugriff (PDF)

Possibilities of using dietary supplements with antioxidant properties in urinary stone disease

Urologii͡a︡ (Moscow, Russia : 1999), 2020-09, Vol.4_2020 (4), p.55-59

2020

Volltextzugriff (PDF)

Investigation of the safety of the product "Rialam."

Voprosy pitaniia, 1999, Vol.68 (1), p.20

1999

Volltextzugriff (PDF)

141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

Annals of oncology, 2022-04, Vol.33, p.S97-S98

2022

Volltextzugriff (PDF)

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

Annals of oncology, 2021-09, Vol.32, p.S1338-S1338

2021

Volltextzugriff (PDF)

379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Annals of oncology, 2020-11, Vol.31, p.S1388-S1389

2020

Volltextzugriff (PDF)

Levels of the individual complement components in the blood serum of volunteers on diets with a various levels of optimal protein composition

Voprosy pitaniia, 1985-07 (4), p.21

1985

Volltextzugriff (PDF)

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Annals of oncology, 2020-09, Vol.31, p.S1212-S1213

2020

Volltextzugriff (PDF)

Determination of acute-inflammatory-phase proteins in the blood serum of volunteers consuming diets with various protein levels consisting of optimum protein constituents

Voprosy pitaniia, 1985-01 (1), p.34

1985

Volltextzugriff (PDF)

Allergic reactions in patients with peptic ulcer; incidence of food and drug allergy

Voprosy pitaniia, 1984-05 (3), p.30

1984

Volltextzugriff (PDF)

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Annals of oncology, 2019-10, Vol.30, p.v928-v929

2019

Volltextzugriff (PDF)

LBA89 - PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Annals of oncology, 2019-10, Vol.30, p.v928-v929

2019

Volltextzugriff (PDF)

LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Annals of oncology, 2019-12, Vol.30, p.xi66

2019

Volltextzugriff (PDF)

LBA89PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

The effect of dietotherapy on the clinico-immunological indices of rheumatoid arthritis patients

Voprosy pitaniia, 1990-01 (1), p.18

1990

Volltextzugriff (PDF)

Отдаленные результаты лечения пациентов с классической лимфомой Ходжкина в реальной клинической практике: опыт гематологического отделения Новосибирска

Kliničeskaâ onkogematologiâ, 2023-03, Vol.16 (2), p.192-199

2023

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(49)

Sprache

Russisch
(27)
Englisch
(22)

Erscheinungsjahr

n.n

Thema

Humans
(25)
Adult
(11)
Middle Aged
(10)
Male
(9)
Dietary Proteins - Administration & Dosage
(8)
Chronic Disease
(7)
Female
(7)
Complement System Proteins - Analysis
(6)
Immunoglobulins - Analysis
(6)
Time Factors
(6)
Immunity, Cellular
(5)
Lymphocyte Activation
(5)
Rheumatic Heart Disease - Immunology
(5)
Aged
(4)
Cytotoxicity, Immunologic
(4)
Recurrence
(4)
T-Lymphocytes - Immunology
(4)
Acute Disease
(3)
Animals
(3)
Blood Proteins - Analysis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta® in the prophylactic treatment of chemotherapy-induced neutropenia

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

256 - Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta® in the prophylactic treatment of chemotherapy-induced neutropenia

Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

The immunological profile of patients with chronic recurrent pancreatitis

Use of basophil degranulation for detecting sensitivity to antigens in rheumatism

Model for detection of the state of delayed hypersensitivity in patients with rheumatism with minimal degree of the activity of the process

Treatment of acute uncomplicated cystitis in women with antibiotic allergy or intolerance

Effect of dietotherapy on the blood serum protein content of patients with torpid and latent recurrent rheumocarditis

Possibilities of using dietary supplements with antioxidant properties in urinary stone disease

Investigation of the safety of the product "Rialam."

141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Levels of the individual complement components in the blood serum of volunteers on diets with a various levels of optimal protein composition

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Determination of acute-inflammatory-phase proteins in the blood serum of volunteers consuming diets with various protein levels consisting of optimum protein constituents

Allergic reactions in patients with peptic ulcer; incidence of food and drug allergy

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

LBA89 - PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

LBA89PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

The effect of dietotherapy on the clinico-immunological indices of rheumatoid arthritis patients

Отдаленные результаты лечения пациентов с классической лимфомой Ходжкина в реальной клинической практике: опыт гематологического отделения Новосибирска

Suchergebnisse filtern